Place · Level 3
Riboflavin
FAD / FMN 电子搬运 · 让其它 B 族也更顺 · 和偏头痛意外相关
Story path
Chapter 1
FAD / FMN cofactors
FAD / FMN cofactors
B2 converts to two active coenzymes in the body:
FMN (flavin mononucleotide): the prosthetic group of respiratory Complex I (NADH dehydrogenase)FAD (flavin adenine dinucleotide): more widely distributed, appearing in Complex II (succinate dehydrogenase), fatty-acid β-oxidation (acyl-CoA dehydrogenase), amino-acid metabolism, and more
Their shared mechanism: the N1–N5 double-bond system on the quinone ring can reversibly accept two electrons and two protons, toggling between oxidized (FAD/FMN) and reduced (FADH₂/FMNH₂) states. This makes them some of the most important 'electron relay stations' in metabolic pathways.
FMN (flavin mononucleotide): the prosthetic group of respiratory Complex I (NADH dehydrogenase)FAD (flavin adenine dinucleotide): more widely distributed, appearing in Complex II (succinate dehydrogenase), fatty-acid β-oxidation (acyl-CoA dehydrogenase), amino-acid metabolism, and more
Their shared mechanism: the N1–N5 double-bond system on the quinone ring can reversibly accept two electrons and two protons, toggling between oxidized (FAD/FMN) and reduced (FADH₂/FMNH₂) states. This makes them some of the most important 'electron relay stations' in metabolic pathways.
Why pee turns bright yellow
'Urine turning fluorescent yellow after B-complex' is B2's visible signature:B2 (riboflavin) is a natural yellow dye (Latin 'flavus' = yellow)Beyond the body's requirements: filtered by the kidneys into urineFluorescent property: under UV light it glows blue-green (this is the principle behind currency-detection lamps)
So:
Yellow urine isn't poor absorption — quite the opposite, it shows the supplement was absorbed into blood and is being properly excreted by the kidneysThe brighter the yellow, the more excess above RDA; doesn't mean 'you wasted it'No yellow appearing: actually might mean the supplement wasn't absorbed, deficient, or under-dosed
Practical tips:
Vitamin-supplement ads that say 'our product doesn't yellow your urine' may indicate that product has low B2 contentFirst morning urine bright yellow: usually B2 (or other), occasional dehydration can also produce yellow but it's dark dim yellow, not brightUrine colors to actually worry about: dark brown / red / strong-tea-colored (rhabdomyolysis, liver disease, hematuria) — unrelated to B2
B2 as a tracer application:
Clinical research uses riboflavin as a medication-adherence marker (compliance marker) — give participants the drug + a small amount of riboflavin, then check urine under UV later → confirms whether they actually took itA classic bit of nutrition cleverness
Chapter 2
Electrons to ATP
Electrons to ATP
FADH₂ feeds electrons into the mitochondrial respiratory chain (entering at Complex II), driving the proton pump and ultimately producing adenosine triphosphate: The cell's universal energy currency — almost everything that costs energy spends it.. Each FADH₂ contributes about 1.5 ATP.
FMN, meanwhile, accepts NADH's electrons at Complex I and passes them through iron-sulfur (Fe-S) clusters downstream.
B2 doesn't make you 'feel energetic' — it just keeps the metabolic electron flow running. When B2 is sufficient you won't be aware of its presence; when insufficient, the first tissues affected are those with high electron throughput (high metabolic-rate cells).
FMN, meanwhile, accepts NADH's electrons at Complex I and passes them through iron-sulfur (Fe-S) clusters downstream.
B2 doesn't make you 'feel energetic' — it just keeps the metabolic electron flow running. When B2 is sufficient you won't be aware of its presence; when insufficient, the first tissues affected are those with high electron throughput (high metabolic-rate cells).
Light destroys B2
B2 is one of the few water-soluble vitamins that's extremely light-sensitive — this affects food storage:Photolytic decomposition:
Visible light + UV light degrade riboflavin to lumiflavin + lumichrome — losing vitamin activityDecomposition rate: strong direct sunlight (clear glass bottle) loses 50%+ in 2–4 hoursMilk in a clear bottle at room temperature for 24 h: ~60% B2 loss
Practical implications:
Milk: stainless steel can / opaque paper carton / dark bottle > clear glass bottleVitamin supplements: amber glass bottles (like traditional Chinese medicine) > clear bottlesFortified cereals: inside opaque packaging
Side effects of neonatal jaundice phototherapy:
Neonatal jaundice is treated with blue light (wavelength ~460 nm) → degrades bilirubinAlso degrades riboflavin in infant plasma and tissues — long phototherapy can cause B2 deficiency → usually no clinical consequence because phototherapy is brief + breast milk supplies B2
Therapeutic application of photo-toxicity reversed:
Corneal cross-linking (CXL) for keratoconus:Drop riboflavin on the cornea → expose to UV-A lightB2 under UV generates oxygen radicals → form extra crosslinks with corneal collagen → cornea stiffens, halting keratoconus progressionStandard protocol 30 minutes; one of the most important ophthalmology advances since the 2010sAn interesting application where B2's 'photo-degradation' becomes a therapeutic tool
Chapter 3
The B-vitamin enabler
The B-vitamin enabler
A low-key role of B2 is helping other B vitamins:
B6 → PLP: the final oxidation step to pyridoxal phosphate (PLP) requires the FMN-dependent pyridoxine-5'-phosphate oxidaseFolate metabolism: the MTHFR enzyme that reduces 5,10-methylene-THF to 5-methyl-THF also needs FAD as a cofactorTryptophan → niacin: the kynurenine hydroxylase step on this synthesis path needs FAD
This shows the B vitamins aren't independent buttons but a coenzyme network of mutual dependence. B2 deficiency can functionally amplify B6 and folate insufficiency — even when their own intake seems adequate.
B6 → PLP: the final oxidation step to pyridoxal phosphate (PLP) requires the FMN-dependent pyridoxine-5'-phosphate oxidaseFolate metabolism: the MTHFR enzyme that reduces 5,10-methylene-THF to 5-methyl-THF also needs FAD as a cofactorTryptophan → niacin: the kynurenine hydroxylase step on this synthesis path needs FAD
This shows the B vitamins aren't independent buttons but a coenzyme network of mutual dependence. B2 deficiency can functionally amplify B6 and folate insufficiency — even when their own intake seems adequate.
MTHFR + B2 pair
MTHFR C677T polymorphism + B2 status is a less-known but clinically meaningful interaction in nutritional genetics:Mechanism:
The MTHFR enzyme converts 5,10-methylene-THF → 5-methyl-THFMTHFR's prosthetic group is FAD (from B2)The C677T mutation makes the enzyme bind FAD more loosely — under low-FAD conditions, activity drops further
Result:
TT homozygote + B2 insufficient → MTHFR activity is much lower than TT + B2 sufficient or CC + B2 insufficientA clean example of 'same genes, different nutrition, different phenotype'
Clinical evidence:
McNulty 2017 RCT (Northern Ireland): MTHFR TT homozygote hypertensive patients → riboflavin 1.6 mg/day × 16 weeks → systolic BP ↓ 5–13 mmHg vs placeboMcNulty 2006: same population, B2 intervention improved HcyCT heterozygote / CC wild-type: B2 intervention had no BP-lowering effect
Practical:
TT homozygote + hypertension / stroke history / high cardiovascular risk + elevated Hcy → small-dose B2 (1.6–5 mg/day) is a low-cost intervention optionA real case of pharmacogenomic individualization — same genotype plus B2 helps these specific people; others don't need to supplement specifically
Important:
Not every MTHFR TT carrier needs B2 — only when combined with clinical evidence (high Hcy / hypertension) does it make sense'Tested MTHFR → must supplement B2' is also direct-sales rhetoric — the evidence points to a specific subgroup
Chapter 4
Deficiency signs
Deficiency signs
Early B2 deficiency signs concentrate on mucous membranes and skin, because these tissues turn over fast and have high electron-flux demand:
Angular stomatitis: cracking at the corners of the mouthCheilitis: dry, red, cracked lipsGlossitis: smooth, red tongue (magenta tongue)Skin dermatitis: nasolabial folds, behind the earsCorneal vascularization: severe cases show eye congestion
Important: these symptoms aren't specific — they also appear with iron, B6, zinc, or other nutrient deficiencies. You can't self-diagnose B2 deficiency by observation; these are cues that 'overall diet quality may be inadequate', not signs unique to B2.
Angular stomatitis: cracking at the corners of the mouthCheilitis: dry, red, cracked lipsGlossitis: smooth, red tongue (magenta tongue)Skin dermatitis: nasolabial folds, behind the earsCorneal vascularization: severe cases show eye congestion
Important: these symptoms aren't specific — they also appear with iron, B6, zinc, or other nutrient deficiencies. You can't self-diagnose B2 deficiency by observation; these are cues that 'overall diet quality may be inadequate', not signs unique to B2.
High-risk groups
B2 deficiency is uncommon in developed regions, but several populations have real risk:Diet-pattern related:
Strict vegan / near-vegan (no dairy or eggs) — dairy is the #1 B2 source; those who avoid milk / eggs may have borderline B2 intakeLactose intolerant + completely no milk / no fortified productsChronic heavy alcohol use — poor intake + reduced absorptionExtreme low-energy diet / dieting / anorexia nervosaElderly living alone + monotonous diet
Disease / drug related:
Hypothyroidism — thyroid hormone affects B2 conversion to FAD/FMN; before T4 treatment, B2 status may look falsely lowBrown syndrome (rare mitochondrial diseases like ACAD9 deficiency) — B2 therapy works because FAD is a cofactor for the affected enzymesTricyclic antidepressants + phenothiazines: inhibit B2 → FAD conversionAntimalarials (quinine / chloroquine): same effectNeonatal phototherapy (see earlier page) — short-term can deplete B2
Pregnancy / lactation:
Pregnancy RDA: 1.4 mg/day (vs adult 1.3)Lactation: 1.6 mg/dayDifferences aren't large; ordinary diet usually suffices
Testing and supplementation:
Erythrocyte glutathione reductase activity coefficient (EGRAC) — gold standard for B2 status; > 1.4 suggests deficiencyRarely done clinically; mostly assess by diet + empirical supplementationSupplements: 5–10 mg/day is several times RDA and safe, non-toxic (B2 has essentially no UL)Migraine prevention (see above page): 400 mg/day long-term
B2 + molybdenum co-deficiency (rare but well-known): trimethylaminuria (TMAU, fish odor syndrome) — an FMO3 enzyme activity problem; some cases respond to B2 + molybdenum + low-choline diet — but this is a very specific metabolic disease, not an ordinary odor problem.
Chapter 5
Migraine: unexpected evidence
Migraine: unexpected evidence
B2 and migraine have an unexpected clinical story.
Mechanistic hypothesis: some migraine patients show reduced mitochondrial function, and B2 (FAD) is core to respiratory Complex I/II — high-dose B2 may boost mitochondrial energy reserves and lower sensitivity to cortical spreading depression.
Evidence (Schoenen et al., Neurology 1998, n=55, double-blind): 400 mg/day B2 × 3 months — 'responder rate' (patients with ≥ 50% attack-frequency reduction) was about 56% vs placebo 19%; absolute effect roughly monthly mean attack count down ≈ 2 (NIH ODS summary). Subsequent meta-analyses support efficacy.
Two number frames to keep distinct: '56% of patients responded' (responder rate) is not '56% reduction in attacks for all patients' — clinical paper abstracts are often misread this way, so we put both numbers together here.
Clinical significance: 400 mg/day is far above RDA (1.1–1.3 mg/day) — pharmacologic dose, not 'eat more B2-rich foods'. People needing migraine prevention should discuss with a doctor; rule out contraindications before self-supplementing high doses.
Limitations: the original Schoenen sample was small (n=55) and the mechanism isn't fully nailed down, but this is one of the few scenarios with strong clinical evidence for B2; AAN/AHS (American Academy of Neurology) guidelines list it as Level B evidence for migraine prevention (same tier as Mg and CoQ10).
Mechanistic hypothesis: some migraine patients show reduced mitochondrial function, and B2 (FAD) is core to respiratory Complex I/II — high-dose B2 may boost mitochondrial energy reserves and lower sensitivity to cortical spreading depression.
Evidence (Schoenen et al., Neurology 1998, n=55, double-blind): 400 mg/day B2 × 3 months — 'responder rate' (patients with ≥ 50% attack-frequency reduction) was about 56% vs placebo 19%; absolute effect roughly monthly mean attack count down ≈ 2 (NIH ODS summary). Subsequent meta-analyses support efficacy.
Two number frames to keep distinct: '56% of patients responded' (responder rate) is not '56% reduction in attacks for all patients' — clinical paper abstracts are often misread this way, so we put both numbers together here.
Clinical significance: 400 mg/day is far above RDA (1.1–1.3 mg/day) — pharmacologic dose, not 'eat more B2-rich foods'. People needing migraine prevention should discuss with a doctor; rule out contraindications before self-supplementing high doses.
Limitations: the original Schoenen sample was small (n=55) and the mechanism isn't fully nailed down, but this is one of the few scenarios with strong clinical evidence for B2; AAN/AHS (American Academy of Neurology) guidelines list it as Level B evidence for migraine prevention (same tier as Mg and CoQ10).
Migraine prevention practice
B2 has reasonably solid evidence for migraine prevention (not acute treatment) — a rare example of a nutrient dose reaching pharmaceutical-tier:Key evidence updates:
Schoenen 1998 (Belgium, n=55, randomized double-blind): 400 mg riboflavin/day × 3 months → responder (patients with ≥ 50% attack-frequency reduction) 56% vs placebo 19%; NIH ODS summary absolute effect ≈ monthly attacks ↓ 2Boehnke 2004 (RCT replication): similar results, mean attack frequency ↓Maizels 2004 (children and adolescents): equally effective2017 systematic review (Thompson, JAMA Pediatrics): pediatric doses 100–400 mg/day effectiveAAN/AHS American Academy of Neurology guideline: places B2 as Level B evidence for migraine prevention ('possibly effective, should be considered'), alongside CoQ10 and magnesium, below valproate / topiramate (Level A)
Therapy tiers (migraine prevention):
| Tier | Intervention | Monthly attack reduction |
|---|---|---|
| First-line drugs | propranolol, topiramate, Botox, CGRP antibodies | 50–75% |
| Nutrient evidence | B2 400 mg, Mg 600 mg, CoQ10 300 mg | 30–50% |
| Behavioral | regular sleep, identifying triggers, exercise | 20–40% |
| Weak evidence | feverfew, magnolia berry, etc. | inconsistent |
Practical protocol (classic):
B2 400 mg/day (single dose or divided) × at least 3 months to evaluate effectCommon side effect: brightened yellow/orange urine — not abnormal (B2 yellow pigment), sign of normal absorptionVery rare adverse reactions — this is B2's advantage as prevention (vs drug cognitive / weight / heart-rate side effects)Can stack with Mg 600 mg + CoQ10 100–300 mg: the 'nutrient triplet' can be tried 3–6 months under physician guidance
Contraindications / cautions:
On methotrexate or similar anti-folate drugs — B2 affects their metabolism; consult physicianPregnancy: high-dose data are limited; within RDA is safeIf pain suddenly changes / new symptoms appear: don't assume migraine, seek prompt medical care to rule out stroke / intracranial lesions
B2 isn't an abortive drug — it doesn't stop acute pain. It's a prevention tool for patients with frequent (≥ 4/month) attacks affecting quality of life, used to reduce attack frequency.